Protagen Oncimmune Buys Protagen for £4.1M The company said that it plans to use Protagen's assets to further the development and commercialization of its EarlyCDT cancer diagnostics. Protagen, NCT Heidelberg Partner to Predict Immunotherapy Response in Urothelial Cancer The project aims to identify biomarkers for predicting response and adverse events in urothelial carcinoma patients receiving immunotherapy. Protagen, NCT, NEC Partner on Prediction of Immunotherapy Response in Melanoma The parties will use machine learning to develop biomarker models for immunotherapy endpoints, including adverse effects, clinical response, and survival. Protagen Shifting to Focus on Cancer Immunotherapy Premium With a series of recent collaborations in hand, the company is leveraging its experience in autoimmune biomarkers to move into the immunoncology space. Protagen, Gustave Roussy Collaborating on Markers for Immunotherapy Side Effects Under the collaboration, they will use Protagen's SeroTag platform to test cancer immunotherapy patients for markers linked to immune-related adverse events. Feb 2, 2017 Protagen, NCI Partner to Identify Cancer Immunotherapy Biomarkers Jan 20, 2017 Immunovia's Blood-Based Array Test for Lupus Advances in New Study Premium Jan 17, 2017 Protagen, German Cancer Center Collaborate on Immunotherapy Biomarkers Aug 11, 2016 Protagen Licenses Systemic Sclerosis Marker to Inova Jun 15, 2016 Protagen Receives CE Mark for BICD2 Systemic Sclerosis Marker Mar 4, 2016 Protagen Using Protein Array Tech for Drug Target ID; Will Release Autoimmune Marker Panels Premium Feb 12, 2016 Researchers From Protagen, Targos, Elsewhere ID Protein Biomarkers for Prostate Inflammation Dec 11, 2015 Protagen Working With MATURA Consortium to Develop Proteomic Test to Predict Drug Response in RA Premium Nov 12, 2015 Protagen, Mikrogen Ink Lyme Disease Diagnostic Deal Jun 24, 2015 Protagen Obtains ISO Certification Dec 16, 2014 Protagen Closes First Part of Financing Round Nov 21, 2014 Qiagen Makes Move toward Proteomics with Protagen CDx Development Deal Premium Nov 17, 2014 Protagen, Qiagen Collaborate to Advance Development of Protein-based CDx for Autoimmune Diseases Sep 5, 2014 New Products: Biognosys, Protagen Premium Dec 3, 2013 Protagen Signs Biomarker Discovery Deal with Pfizer Jul 2, 2013 Protagen Sells Protein Services Subsidiary in Shift Toward Focus on Dx Development Mar 16, 2012 Protagen and NMI Collaborating on Protein Dx for Cancer and Autoimmune Diseases Premium Mar 16, 2012 Protagen, NMI Developing Assays for Autoimmune Diseases, Cancer Dec 7, 2011 Protagen, Bayer Partner on Biomarkers for Endometriosis Oct 28, 2011 Protagen, Charles River Ink Protein Analysis Services Alliance Load More Breaking News European Commission Outlines Intended Restorative Measures for Blocked Illumina-Grail Deal Cross-Trait Meta-Analysis Explores Potential Pleiotropy Across Psychiatric Conditions Bactobio Raises £6M in Private Financing Top Five Articles on GenomeWeb Last Week: Amazon Omics, Ashkenazi Jewish Population History, More AnPac Bio to Raise $5M in Private Placement The Scan Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases. Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes. Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach. Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.